Royal London Asset Management LTD Biogen Inc. Transaction History

Royal London Asset Management LTD

$38.5 Billion
Q2 2024

A detailed history of Royal London Asset Management LTD transactions in Biogen Inc. stock. As of the latest transaction made, Royal London Asset Management LTD holds 69,572 shares of BIIB stock, worth $13.5 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

69,572

Previous 56,821 22.44%

Holding current value

$13.5 Million

Previous $12.3 Million 31.64%

% of portfolio

0.04%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$190.52 - $236.72 $2.43 Million - $3.02 Million	12,751 Added 22.44%	69,572 $16.1 Million
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $83,535 - $105,477	-394 Reduced 0.69%	56,821 $12.3 Million
Q4 2023 Feb 13, 2024	SELL	$222.59 - $267.94 $783,516 - $943,148	-3,520 Reduced 5.8%	57,215 $14.8 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $2.41 Million - $2.71 Million	-9,495 Reduced 13.52%	60,735 $15.6 Million
Q2 2023 Aug 11, 2023	SELL	$275.25 - $318.06 $7.2 Million - $8.32 Million	-26,145 Reduced 27.13%	70,230 $20 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $11.4 Million - $13 Million	-44,443 Reduced 31.56%	96,375 $26.8 Million
Q4 2022 Feb 09, 2023	SELL	$252.44 - $306.72 $3.71 Million - $4.51 Million	-14,693 Reduced 9.45%	140,818 $39 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $10 Million - $13.9 Million	51,613 Added 49.68%	155,511 $41.5 Million
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $161,847 - $192,466	-863 Reduced 0.82%	103,898 $21.2 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $741,557 - $934,323	3,827 Added 3.79%	104,761 $22.1 Million
Q4 2021 Oct 18, 2022	SELL	$223.92 - $287.77 $1.47 Million - $1.89 Million	-6,572 Reduced 6.11%	100,934 $24.2 Million
Q4 2021 Jan 18, 2022	SELL	$223.92 - $287.77 $1.47 Million - $1.89 Million	-6,572 Reduced 6.11%	100,934 $24.2 Million
Q3 2021 Oct 18, 2022	SELL	$282.99 - $369.05 $982,541 - $1.28 Million	-3,472 Reduced 3.13%	107,506 $30.4 Million
Q3 2021 Nov 02, 2021	SELL	$282.99 - $369.05 $982,541 - $1.28 Million	-3,472 Reduced 3.13%	107,506 $30.4 Million
Q2 2021 Oct 18, 2022	BUY	$259.0 - $414.71 $1.83 Million - $2.94 Million	7,080 Added 6.81%	110,978 $38.5 Million
Q2 2021 Jul 14, 2021	SELL	$259.0 - $414.71 $1.57 Million - $2.52 Million	-6,069 Reduced 5.19%	110,978 $38.5 Million
Q1 2021 Oct 17, 2022	BUY	$242.95 - $284.63 $3.19 Million - $3.74 Million	13,149 Added 12.66%	117,047 $32.8 Million
Q1 2021 Apr 13, 2021	BUY	$242.95 - $284.63 $965,726 - $1.13 Million	3,975 Added 3.52%	117,047 $32.7 Million
Q4 2020 Jan 29, 2021	BUY	$236.26 - $355.63 $476,536 - $717,305	2,017 Added 1.82%	113,072 $27.7 Million
Q3 2020 Nov 04, 2020	SELL	$264.77 - $305.71 $523,450 - $604,388	-1,977 Reduced 1.75%	111,055 $31.4 Million
Q2 2020 Jul 31, 2020	SELL	$258.66 - $342.55 $2.19 Million - $2.9 Million	-8,474 Reduced 6.97%	113,032 $29.4 Million
Q1 2020 May 01, 2020	BUY	$268.85 - $341.04 $541,732 - $687,195	2,015 Added 1.69%	121,506 $38.4 Million
Q4 2019 Feb 05, 2020	SELL	$220.06 - $304.07 $530,784 - $733,416	-2,412 Reduced 1.98%	119,491 $35.4 Million
Q3 2019 Nov 12, 2019	SELL	$217.44 - $243.88 $214,395 - $240,465	-986 Reduced 0.8%	121,903 $28.4 Million
Q2 2019 Jul 31, 2019	SELL	$219.29 - $241.72 $269,507 - $297,073	-1,229 Reduced 0.99%	122,889 $28.7 Million
Q1 2019 Apr 30, 2019	BUY	$216.71 - $338.96 $2.03 Million - $3.18 Million	9,382 Added 8.18%	124,118 $0
Q4 2018 Jan 29, 2019	BUY	$278.5 - $352.75 $7.26 Million - $9.2 Million	26,068 Added 29.4%	114,736 $33.7 Million
Q3 2018 Nov 08, 2018	SELL	$293.51 - $383.83 $793,064 - $1.04 Million	-2,702 Reduced 2.96%	88,668 $0
Q2 2018 Sep 19, 2018	BUY	$257.52 - $306.91 $23.5 Million - $28 Million	91,370 New	91,370 $26.5 Million

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $27.9B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Royal London Asset Management LTD with notifications on news.

Account

Royal London Asset Management LTD Biogen Inc. Transaction History